نتایج جستجو برای: gaucher type 1

تعداد نتایج: 3648308  

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1990
N W Barton F S Furbish G J Murray M Garfield R O Brady

Enzyme replacement has been under consideration as a therapeutic strategy for patients with Gaucher disease for more than two decades. Previous studies indicated that single injections of purified glucocerebrosidase reduced the amount of storage material in the liver. It was important to determine whether administration of exogenous enzyme on a regular basis would be of clinical benefit. We rep...

Journal: :Journal of child neurology 2007
Christopher M Harris Pauline Campbell

Recently, it has been claimed that patients with Gaucher disease type 1 have subclinical neurological signs as indicated by electrophysiological measurements. These findings, if substantiated, are very significant in the management of Gaucher disease. In type 1 disease (nonneuronopathic), enzyme replacement therapy is the therapy of choice, with substantial biomedical correction achieved in mos...

2012
Ju-Young Lee Beom Hee Lee Gu-Hwan Kim Chang-Woo Jung Jin Lee Jin-Ho Choi Han-Wook Yoo

PURPOSE Gaucher disease is caused by a β-glucocerebrosidase (GBA) deficiency. The aim of this study is to investigate the clinical and genetic characteristics according to subtypes of Gaucher disease in the Korean population. METHODS Clinical findings at diagnosis, GBA mutations, and clinical courses were reviewed in 20 patients diagnosed with Gaucher disease. RESULTS Eleven patients were d...

2017
Mario de la Mata David Cotán Manuel Oropesa-Ávila Marina Villanueva-Paz Isabel de Lavera Mónica Álvarez-Córdoba Raquel Luzón-Hidalgo Juan M. Suárez-Rivero Gustavo Tiscornia José A. Sánchez-Alcázar

BACKGROUND Gaucher disease (GD) is caused by mutations in the GBA1 gene which encodes lysosomal β-glucocerebrosidase (GCase). In GD, partial or complete loss of GCase activity causes the accumulation of the glycolipids glucosylceramide (GlcCer) and glucosylsphingosine in the lysosomes of macrophages. In this manuscript, we investigated the effects of glycolipids accumulation on lysosomal and mi...

Journal: :Genetics and molecular research : GMR 2015
Y Zhang Y F Mao J M Du

A 49-year-old man with a history of Gaucher disease type 1, resulting in serious splenomegaly and eating disorder, was referred to our department and underwent a splenectomy under general anesthesia. Gaucher disease is very rare, and its first signs are unexplained splenomegaly and hypersplenism. On preoperative examination, the patient's platelet count was slightly low, and his other test resu...

Journal: :Blood cells, molecules & diseases 1999
L Lacerda F A Arosa R Lacerda J Cabeda G Porto O Amaral A Fortuna R Pinto P Oliveira C E McLaren C Sá Miranda M de Sousa

The major elements of bone pathology in Gaucher disease are a failure of osteoclast and osteoblast function, resulting in osteopenia and also osteonecrosis. T lymphocytes have recently been found to be involved in the regulation of osteoblast/osteoclast activity in vitro. In the present report the peripheral blood T major lymphocyte subsets were investigated in a group of genotyped type 1 Gauch...

2015
Stefano Raffaele Giannubilo Angela Pasculli Elisa Tidu Andrea Ciavattini

BACKGROUND Gaucher disease is a lysosomal storage disorder due to deficiency of glucocerebrosidase enzyme. In this study, a case of enzyme-treated woman during her pregnancy was reported. CASE PRESENTATION A 27-year old woman with type I Gaucher disease was managed for pregnancy until delivery. She underwent elective splenectomy at age 26 years and was treated with 19-38 units/kg of imiglucer...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید